Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16, 2024 14:06 ET
|
Spherix Global Insights
EXTON, PA, April 16, 2024 (GLOBE NEWSWIRE) -- In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA),...
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 11, 2024 16:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
Waiting for new medicines in Canada, Europe, and the United States: Study finds Americans get better and faster access to innovative drugs
April 11, 2024 10:30 ET
|
Canadian Health Policy Institute Inc.
Americans get better and faster access to innovative medicines compared to Europeans and Canadians.
Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients
April 11, 2024 10:00 ET
|
Canadian Health Policy Institute Inc.
A recent study published by the Canadian Health Policy Institute examined the availability and wait times for access to new drugs.
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
April 05, 2024 09:17 ET
|
Spherix Global Insights
EXTON, PA, April 05, 2024 (GLOBE NEWSWIRE) -- As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra...
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
April 05, 2024 09:00 ET
|
IR-Med, Inc.
Marks major milestone prior to launch in U.S. marketPressureSafe™ scanner and disposable pack both listed with FDAPressureSafe™ can support early detection of pressure injuries, potentially setting a...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action – INMD
April 02, 2024 15:42 ET
|
The Rosen Law Firm PA
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
April 02, 2024 08:31 ET
|
NurExone Biologic Inc
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
ROSEN, A LEADING LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
March 28, 2024 11:28 ET
|
The Rosen Law Firm PA
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...